Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis

Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis

Abstract Background Controlled and real-world evidence have demonstrated the efficacy of calcitonin gene related peptide (CGRP) monoclonal antibodies (MABs) in migraine. However, data on the over-one-year sustained effectiveness of CGRP MABs in resistant chronic migraine (CM) is sparse. Methods Thi...

Full description

Bibliographic Details
Main Authors:	Anna P. Andreou, Matteo Fuccaro, Bethany Hill, Madeleine Murphy, Valeria Caponnetto, Rachael Kilner, Giorgio Lambru
Format:	Article
Language:	English
Published:	BMC 2022-11-01
Series:	The Journal of Headache and Pain
Subjects:	Erenumab Chronic migraine Resistant migraine CGRP Monoclonal antibodies
Online Access:	https://doi.org/10.1186/s10194-022-01507-8

Similar Items

A prospective real-world analysis of erenumab in refractory chronic migraine
by: Giorgio Lambru, et al.
Published: (2020-06-01)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
by: Agaath Hedina Manickam, et al.
Published: (2021-08-01)

Erenumab efficacy predictors for chronic migraine
by: Nina V. Vashchenko
Published: (2022-02-01)

Erenumab effectiveness and safety: comparison of real-life data and clinical trial results
by: Austėja Dapkutė, et al.
Published: (2021-12-01)

Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study
by: Charly Gaul, et al.
Published: (2024-10-01)

One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study
by: M. Lanteri-Minet, et al.
Published: (2023-11-01)

The course of headache after the end of treatment with erenumab in patients with episodic and chronic migraine
by: Anna A. Garmanova, et al.
Published: (2024-05-01)

Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation
by: Michael Lowe, et al.
Published: (2022-07-01)

Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea
by: Anna V. Berdnikova, et al.
Published: (2023-10-01)

Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
by: Antonio Russo, et al.
Published: (2020-06-01)

A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine
by: Saval Khanal, et al.
Published: (2022-09-01)

Serum CGRP in migraine patients using erenumab as preventive treatment
by: Simone de Vries Lentsch, et al.
Published: (2022-09-01)

Six-month therapy of CGRP monoclonal antibodies in real-world clinical practice: an interim analysis of efficacy and safety data
by: N. V. Vashchenko, et al.
Published: (2022-01-01)

Assessment and characteristics of Erenumab therapy on migraine management
by: Haitham Saeed, et al.
Published: (2022-08-01)

Erenumab Impact on Sleep Assessed With Questionnaires and Home-Polysomnography in Patients With Migraine: The ERESON Study
by: Gaia Pellitteri, et al.
Published: (2022-05-01)

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study
by: Hannah Schenk, et al.
Published: (2022-05-01)

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
by: Armin Scheffler, et al.
Published: (2020-07-01)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
by: Magdalena Nowaczewska, et al.
Published: (2022-05-01)

Assessment of prolonged safety and tolerability of erenumab in migraine patients in a long-term open-label study (APOLLON)
by: Hartmut Göbel, et al.
Published: (2024-09-01)

Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
by: Roberto De Icco, et al.
Published: (2022-09-01)

Real-world effectiveness of erenumab in Japanese patients with migraine
by: Keisuke Suzuki, et al.
Published: (2024-02-01)

Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety
by: M. T. Corasaniti, et al.
Published: (2023-12-01)

Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
by: Taoufik Alsaadi, et al.
Published: (2022-06-01)

Migraine Treatment Using Erenumab: Can Lead to a Cognitive and Psychological Qualitative Improvement?
by: Michele Torrisi, et al.
Published: (2023-05-01)

Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study
by: Christopher Kjaer Cullum, et al.
Published: (2023-08-01)

Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01)

Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany
by: Ja Bin Hong, et al.
Published: (2023-10-01)

A case report of a chronic migraine patient treated with three different anti-CGRP monoclonal antibodies: which parameters better represent the efficacy?
by: Sena Uzun, et al.
Published: (2023-05-01)

Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
by: Raffaele Ornello, et al.
Published: (2021-12-01)

Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
by: Raffaele Ornello, et al.
Published: (2021-03-01)

Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review
by: Tulsi Shah, et al.
Published: (2023-03-01)

Monoclonal antibodies blocking CGRP for prevention of migraine
by: Alicja Maziarczyk, et al.
Published: (2023-04-01)

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
by: Shigekazu Kitamura, et al.
Published: (2023-09-01)

MicroRNA profiling in women with migraine: effects of CGRP-targeting treatment
by: Raffaele Ornello, et al.
Published: (2024-05-01)

A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study
by: Shengyuan Yu, et al.
Published: (2022-11-01)

Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review
by: Suruchi Aditya, et al.
Published: (2023-01-01)

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
by: Varnado OJ, et al.
Published: (2024-01-01)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor
by: Hans-Christoph Diener, et al.
Published: (2020-04-01)

Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis
by: Patricia Pozo-Rosich, et al.
Published: (2024-03-01)

Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)
by: Elizabeth Seng, et al.
Published: (2024-09-01)